arrow
B

Brigitta G. Baumert

cantonal hospital graubünden
H指数:58
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Health-Related Quality of Life in Glioma Subtypes: A Pooled Analysis of 16 Randomized Trials from the CODAGLIO 2.0 project

胶质瘤亚型相关的健康生活质量:CODAGLIO 2.0项目16项随机试验的合并分析

2026-10-010
OAAI
Age and sex as risk factors for health-related quality of life outcomes in patients with glioma: a CODAGLIO 2.0 analysis

年龄和性别作为胶质瘤患者健康相关生活质量结果的风险因素:CODAGLIO 2.0分析

2026-03-010
OA
Corrigendum to “ESTRO/EANO recommendation on reirradiation of glioblastoma” [Radiother. Oncol. 204 (2025) 110696]

勘误:“ESTRO/EANO关于胶质母细胞瘤再照射的建议”[Radiother. Oncol. 204 (2025) 110696]

2026-02-180
PRE
Health-Related Quality of Life in Molecular Glioma Subtypes: A Pooled Analysis from 16 Randomized Trials

分子胶质瘤亚型的健康相关生活质量:一项来自16项随机试验的合并分析

2025-11-010
OAAI
AGE AND SEX AS RISK FACTORS FOR HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN GLIOMA PATIENTS: POOLED ANALYSES OF CLINICAL TRIALS FROM THE CODAGLIO 2.0 DATABASE

年龄和性别作为健康相关生活质量结局的危险因素:来自CODAGLIO 2.0数据库临床试验的合并分析

2025-10-010
OAAI
FINAL CLINICAL AND MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1P/19Q CODELETION.

EORTC随机分组III期CATNON试验的最终临床和分子分析:关于无1p/19q共缺失的间变性胶质瘤中同步和辅助替莫唑胺的应用。

2025-10-010
OAAI
Dose-intensified SBRT for vertebral oligometastases: results from a prospective clinical trial

剂量强化SBRT治疗椎体寡转移瘤:前瞻性临床试验结果

2025-07-010
OA
ESTRO/EANO recommendation on reirradiation of glioblastoma

关于胶质母细胞瘤再照射的ESTRO/EANO建议

2025-03-011
PRE
RADIOTHERAPY VERSUS TMZ FOR HIGH-RISK LOW-GRADE GLIOMA. FINAL RESULTS AFTER MEDIAN FOLLOW-UP OF 13 YEARS OF PHASE III EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) STUDY
2024-11-110
PRE
AMINO-ACID PET VERSUS MRI GUIDED RE-IRRADIATION IN PATIENTS WITH RECURRENT GLIOBLASTOMA - GLIAA TRIAL (NOA 10/ARO 2013-1, DKTK-A)
2024-10-170
PRE
Dose-intensified stereotactic body radiotherapy for painful vertebral metastases: A randomized phase 3 trial

剂量强化立体定向放射治疗疼痛性椎体转移瘤: 一项随机3期试验

CANCER
IF5.1
2024-04-068
OAAI
Pharmazeutische Behandlung der akuten Radiodermatitis in der deutschsprachigen strahlentherapeutischen Gemeinschaft
2024-02-150
OAAI
Pharmaceutical management of acute radiation dermatitis in the German speaking radiation oncology community
2023-12-134
OAAI
Re-irradiation in clinical practice: Results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platform

临床实践中的再照射: 在estro-eortc E2-RADIatE平台框架内进行的国际护理模式调查的结果

2023-12-0115
OAAI
Impact of COVID-19 pandemic on older cancer patients: Proposed solution by the International Geriatric Radiotherapy Group
2023-03-076
OAAI
Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033

有丝分裂计数在没有CDKN2A/B纯合缺失的IDH突变型星形细胞瘤中是预后的。EORTC试验26053 (CATNON) 和EORTC试验22033的共识小组审查结果-26033

2022-12-2611
OA
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions
2022-10-1294
OA